Nicotinamide as an Early Alzheimer's Disease Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-12

Study Completion Date

2022-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Nicotinamide to Treat Alzheimer's Disease

NCT00580931

Alzheimer's Disease

COMPLETED PHASE1/PHASE2

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

NCT04078178

Cognition Disorders in Old Age Mild Cognitive Impairment Cognitive Decline

COMPLETED NA

Nicotinic Acid for the Treatment of Alzheimer's Disease

NCT06582706

Alzheimer Disease

RECRUITING PHASE1/PHASE2

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517

Mild Cognitive Impairment Mild Alzheimer Disease

RECRUITING EARLY_PHASE1

Alzheimer's Disease: Potential Benefit of Isoflavones

NCT00205179

Alzheimer's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nicotinamide, the amide of nicotinic acid (vitamin B3/niacin), is an oral therapy with a wealth of clinical data in a variety of therapeutic areas, including preliminary data supporting its safety in Alzheimer's disease (AD). Preclinical work in a mouse model that develops both plaques and tangles supports the hypothesis that nicotinamide can act as a histone deacetylase (HDAC) inhibitor to reduce phosphorylation of tau.

The study will implement a group sequential design, incorporating a futility analysis with a go/no-go decision conditional on cerebral spinal fluid CSF biomarker outcomes at 12-months. The primary outcome for the trial is change in p-tau231.

This study timeline includes a screening phase of up to 60 days and treatment phase which is expected to last about 48 weeks and will include 4 study visits.

An additional 12-month treatment and follow-up period is planned, contingent upon a "go" decision based on the primary outcome (CSF p-tau231) or one planned secondary outcome (CSF p-tau181)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Double-Blind-Randomized

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nicotinamide

1500mg twice daily: 2, 750mg tablets taken orally twice daily

Group Type EXPERIMENTAL

Nicotinamide

Intervention Type DRUG

Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.

Placebo

1500mg twice daily: 2, 750mg tablets taken orally twice daily

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

Oral Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotinamide

Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.

Intervention Type DRUG

Placebo Comparator

Oral Tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Niacinamide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)
2. Biomarker criteria:

Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (Aβ42) \<= 600 pg/mL, or A ratio of total tau to Aβ42 ≥ 0.39.
3. Mini-Mental State Exam (MMSE) ≥ 20
4. Blood laboratories, urinalysis, and electrocardiogram are within normal limits or deemed clinically not significant by the site investigator
5. Stable medications (including approved AD therapies) for at least 4 weeks
6. At least 6 years of education
7. Able to swallow oral tablets
8. Speaks English fluently
9. Available qualified study partner (≥3 times per week in-person communication with the participant)

Exclusion Criteria

1. Active neurological or psychiatric diagnosis other than AD that may affect cognition and/or function. (Obstructive sleep apnea is permitted, if treated.)
2. Inability to undergo lumbar puncture, including use of Coumadin, novel oral anticoagulants, clopidogrel, or dipyridamole. Use of aspirin \<= 325mg daily is permitted.
3. Hachinski ischemic scale \> 4
4. Magnetic Resonance Imaging (MRI) incompatibility
5. MRI evidence of cortical stroke \>1cm, superficial siderosis, or extensive white matter hyperintensity (Cardiovascular Health Study score 7-8+)
6. Diagnosis of cancer in the previous 5 years (with the exception of basal or squamous cell carcinoma)
7. Geriatric Depression Scale (GDS) score \>6
8. History within the past 5 years of alcohol or substance use disorder
9. Laboratory evidence of a clinically significant abnormality that may interfere with study assessments
10. Active partial or total malabsorptive disease (e.g., celiac disease)
11. Resides in a skilled nursing facility
12. Participation in a clinical trial of a potential disease-modifying therapy for AD in previous 6-months (time between last investigational drug administration and baseline for the current study)
13. Pregnant, lactating or of child bearing potential (that is, women must be 2 years post-menopausal or surgically sterile to be considered not child bearing potential).
14. Unwillingness to abstain from over-the-counter nicotinamide for the duration of the trial

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No